The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial
Open accessAbstract
IMPORTANCE: Patients with unresectable intrahepatic cholangiocarcinoma (ICC) have a poor prognosis. Selective internal radiotherapy (SIRT) is a promising treatment option for hepatic tumors, but no prospective studies of combination SIRT with chemotherapy have been published to our knowledge. OBJECTIVE: To determine the response rate after SIRT combined with chemotherapy in patients with unresectable ICC. DESIGN, SETTING, AND PARTICIPANTS: This phase 2 clinical trial, the Yttrium-90 Microspheres in Cholangiocarcinoma (MISPHEC) trial, included patients with unresectable ICC who have never received chemotherapy or intra-arterial therapy and were treated at 7 centers which had experience with SIRT between November 12, 2013, and June 21, 2016. Statistical analysis was performed from March 31, 2017, to June 17, 2019. INTERVENTIONS: Concomitant first-line chemotherapy with cisplatin, 25 mg/m2, and gemcitabine, 1000 mg/m2 (gemcitabine reduced to 300 mg/m2 for the cycles just before and after SIRT), on days 1 and 8 of a 21-day cycle for 8 cycles. Selective internal radiotherapy was administered during cycle 1 (1 hemiliver disease) or cycles 1 and 3 (disease involving both hemilivers) using glass Y90 microspheres. MAIN OUTCOMES AND MEASURES: Response rate at 3 months according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Secondary end points were toxic effects, progression-free survival, overall survival, disease control rate, and response rate according to Choi criteria. RESULTS: Of 41 patients included in the study, 26 (63%) were male, with a mean (SD) age of 64.0 (10.7) years. Response rate according to RECIST was 39% (90% CI, 26%-53%) at 3 months according to local review and was confirmed at 41% as best response by central review; disease control rate was 98%. According to Choi criteria, the response rate was 93%. After a median follow-up of 36 months (95% CI, 26-52 months), median progression-free survival was 14 months (95% CI, 8-17 months), with progression-free survival rates of 55% at 12 months and 30% at 24 months. Median overall survival was 22 months (95% CI, 14-52 months), with overall survival rates of 75% at 12 months and 45% at 24 months. Of 41 patients, 29 (71%) had grades 3 to 4 toxic effects; 9 patients (22%) could be downstaged to surgical intervention, with 8 (20%) achieving R0 (microscopic-free margins) surgical resection. After a median of 46 months (95% CI, 31 months to not reached) after surgery, median relapse-free survival was not reached among patients who underwent resection. CONCLUSIONS AND RELEVANCE: Combination chemotherapy and SIRT had antitumor activity as first-line treatment of unresectable ICC, and a significant proportion of patients were downstaged to surgical intervention. A phase 3 trial is ongoing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
Bridgewater, J., Galle, P. R., Khan, S. A., Llovet, J. M., Park, J.-W., Patel, T., Pawlik, T. M., & Gores, G. J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.021 · Cited by 1,511
Primrose, J. N., Fox, R. P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D., Anthony, A., Corrie, P., Falk, S., Finch-Jones, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30915-x · Cited by 1,273
Okusaka, T., Nakachi, K., Fukutomi, A., Mizuno, N., Ohkawa, S., Funakoshi, A., Nagino, M., Kondo, S., Nagaoka, S., Funai, J., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605779 · Cited by 744
Burden of Digestive Diseases in the United States Part III: Liver, Biliary Tract, and Pancreas
Everhart, J. E., & Ruhl, C. E. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.038 · Cited by 710
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Valle, J. W., Borbath, I., Khan, S. A., Huguet, F., Gruenberger, T., & Arnold, D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw324 · Cited by 675
Edeline, J., Benabdelghani, M., Bertaut, A., Watelet, J., Hammel, P., Joly, J.-P., Boudjema, K., Fartoux, L., Bouhier-Leporrier, K., Jouve, J.-L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00050 · Cited by 541
Self-citation
Cited by
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Vogel, A., Bridgewater, J., Edeline, J., Kelley, R. K., Klümpen, H. J., Malka, D., Primrose, J. N., Rimassa, L., Stenzinger, A., Valle, J. W., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.506 · Cited by 718
Self-citationGarin, E., Tselikas, L., Guiu, B., Chalaye, J., Edeline, J., de Baere, T., Assenat, E., Tacher, V., Robert, C., Terroir-Cassou-Mounat, M., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30290-9 · Cited by 630
Self-citationMoris, D., Palta, M., Kim, C., Allen, P. J., Morse, M. A., & Lidsky, M. E. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21759 · Cited by 451
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
Lamarca, A., Barriuso, J., McNamara, M. G., & Valle, J. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.007 · Cited by 367
Liver resection and transplantation for intrahepatic cholangiocarcinoma
Mazzaferro, V., Gorgen, A., Roayaie, S., Droz dit Busset, M., & Sapisochin, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.020 · Cited by 355
Metadata
- Authors
- Edeline, J., Touchefeu, Y., Guiu, B., Farge, O., Tougeron, D., Baumgaertner, I., Ayav, A., Campillo-Gimenez, B., Beuzit, L., Pracht, M., Lièvre, A., Le Sourd, S., Boudjema, K., Rolland, Y., Boucher, E., & Garin, E.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2020-01-01
- Volume
- 6
- Issue
- 1
- Pages
- 51
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2982321050
- Cited by
- 306
- References
- 24
- FWCI
- 25.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2019.3702
- The paper
- Edeline, J., Touchefeu, Y., Guiu, B., Farge, O., Tougeron, D., Baumgaertner, I., Ayav, A., Campillo-Gimenez, B., Beuzit, L., Pracht, M., Lièvre, A., Le Sourd, S., Boudjema, K., Rolland, Y., Boucher, E., & Garin, E. (2020). Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2019.3702
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.